Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates

Su, Hsiang-Yu; Chiu, Yi-Shu; Chiu, Chuan-Tai; Lin, Yi-Ting; Wang, Chenyu; Hsieh, Jui-Ying; Wei, Shu–Chen

doi:10.1016/j.jfma.2018.07.005

Cited by 72 publications

(75 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, clinicians should be advised to change their treatment strategy for patients with CD; 5-ASA only exhibits a marginal effect on CD, and our results indicated that incidence of intraabdominal abscess increased when disease activity was not fully under control. A relatively low number of cases with therapy escalation were identified among the UC patients because of concerns regarding the adverse effects of immunosuppressants and because the NHI began reimbursing patients for anti-TNF-α agents in September 2016 [ 41 ]. The “treat to target” idea appeared to have been implemented during the present study period; we identified relatively high numbers of patients who had received immunomodulators and biologics.…”

Section: Discussionmentioning

confidence: 99%

Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015

Tung

Chang

Leong³

et al. 2018

JCM

Self Cite

View full text Add to dashboard Cite

Background: No nationwide, long-term follow-up study has assessed medication-associated outcomes for Asian patients with inflammatory bowel disease (IBD). This study examined medication-associated outcomes for Taiwanese patients with IBD. Methods: In this nationwide cohort study, 3806 patients who had received catastrophic illness registration for IBD from 2001 to 2015 were enrolled. Results: A higher accumulated dosage of 5-aminosalicylic acid (5-ASA) was associated with decreased risks of hospitalization (hazard ratio (HR) = 0.6) and operation (HR = 0.5). Thiopurine was associated with increased risks of hospitalization (HR = 2.1 in the high-dosage group) and tuberculosis (TB; HR = 3.6) reactivation but not with operation risk. A higher accumulated dosage of anti-TNF-α agents was associated with increased risks of hospitalization (HR = 3.3), operation (HR = 2.9), hepatitis B (HR = 4.3), and TB (HR = 5.1) reactivation. Corticosteroids were associated with increased risks of hospitalization (HR = 3.5 in the high-dosage group), risk of operation, hepatitis B (HR = 2.8) and TB (HR = 2.8) reactivation. Conclusions: 5-ASA usage is associated with decreased risks of hospitalization and operation for patients with IBD, whereas thiopurine, corticosteroids, and anti-TNF-α agents are associated with increased risks of hospitalization and hepatitis B and TB reactivation.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015

Tung

Chang

Leong³

et al. 2018

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…IBD is a catastrophic illness in Taiwan and proof of diagnoses has to be reviewed by special committee. The diagnosis of IBD was based on medical history, clinical evaluation, endoscopic findings, and histological findings [ 24 , 25 ]. Censoring was defined as death, the date of diagnosis of IBD, or the end of the follow-up period on 31 December 2013.…”

Section: Methodsmentioning

confidence: 99%

Increased Risk of Ulcerative Colitis in Patients with Periodontal Disease: A Nationwide Population-Based Cohort Study

Lin

Tseng

Liu

et al. 2018

IJERPH

View full text Add to dashboard Cite

Both periodontal disease (PD) and inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are important diseases of the alimentary tract. Microbiome and immune-mediated inflammatory processes play important roles in these diseases. An association between PD and IBD may exist. This study investigated the risk of IBD in patients with PD. This study used data from the National Health Insurance Research Database of Taiwan from 1996 to 2013. A total of 27,041 patients with PD were enrolled as a study group, and 108,149 patients without PD were selected as the control group after matching by gender, age, insured region, urbanization, and income with a 1:4 ratio. Cox proportional hazards regression was used to calculate the risk of IBD. Of the 135,190 participants enrolled in this study, 5392 (4%) with newly diagnosed IBD were identified. The overall incidence of subsequent IBD was similar in both groups (3.8% vs. 4%, adjusted hazard ratio (aHR) = 1.01, 95% confidence interval (CI): 0.94–1.08). However, an increased risk of UC in the PD group was found after adjusting confounding factors (aHR: 1.56, 95% CI: 1.13–2.15; p < 0.05). This study demonstrated that patients with PD had approximately one-half higher risk of subsequent UC. Further studies are warranted to elucidate the relationship between PD and UC.

show abstract

“…Inflammatory bowel disease (IBD) has two main forms, including Crohn's disease (CD) and ulcerative colitis (UC). UC is a chronic relapsing disease of the colon and rectum characterized by inflammation and ulceration of the mucosa (Su et al, ). Bloody mucoid stool, diarrhea, and rectal urgency are common gastrointestinal manifestations of UC.…”

Section: Introductionmentioning

confidence: 99%

The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis

Sadeghi

Mansoori

Shayesteh

et al. 2019

Phytotherapy Research

110

View full text Add to dashboard Cite

Background and aims Curcumin has anti‐inflammatory properties. The aim of this study was to evaluate the effect of curcumin on improvement of the disease activity in ulcerative colitis (UC). Methods In this randomized double‐blind clinical trial, 70 patients with mild‐to‐moderate UC were randomly assigned to curcumin (1,500 mg/day) or placebo intake for 8 weeks. Disease clinical activity, quality of life, serum levels of tumor necrosis factor alpha (TNF‐α), high‐sensitivity C‐reactive protein (hs‐CRP), erythrocyte sedimentation rate (ESR) values, and complete blood count were measured. Results Changes in Simple Clinical Colitis Activity Index score were significantly higher in the curcumin than the placebo group (–5.9 ± 2.08 vs. –2.1 ± 2.6; p = .001). The scores of Inflammatory Bowel Disease Questionnaire‐9 and quality of life were significantly higher in the intervention group compared to the control group (p = .006). Furthermore, the curcumin supplementation reduced the serum hs‐CRP concentration (–6.3 ± 13.6 vs. 3.7 ± 11.6 μg/ml; p = .01) and ESR levels significantly (–1.6 ± 2.7 vs. –0.09 ± 2.4 mm/hr; p = .02) in comparison with the control group. No significant changes were observed in the TNF‐α levels of both groups. Conclusions Consumption of the curcumin supplement, along with drug therapy, is associated with significant improvement of the clinical outcomes, quality of life, hs‐CRP, and ESR in patients with mild‐to‐moderate UC.

show abstract

Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates

Cited by 72 publications

References 84 publications

Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015

Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015

Increased Risk of Ulcerative Colitis in Patients with Periodontal Disease: A Nationwide Population-Based Cohort Study

The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis

Contact Info

Product

Resources

About